Key Highlights

• Oramed Pharmaceuticals (NASDAQ: ORMP) approved amended bylaws simplifying stockholder consent procedures under Delaware law.

• Scilex Holding Company extended repayment of approximately $29.5 million in outstanding note obligations to September 30, 2026.

• Oramed received $0.5 million upfront, with $5 million due by July 31, 2026, under the new debt agreement.

• Failure to meet the deadline triggers a $1.5 million non-refundable extension fee and potential equity conversion.

Oramed Pharmaceuticals (NASDAQ: ORMP) has revised its corporate governance framework while securing a critical extension for debt owed by Scilex Holding Company. The moves reflect efforts to streamline operations and manage liquidity amid ongoing financial obligations.

Bylaw Revisions Approved

Oramed’s board adopted the Fifth Amended and Restated Bylaws on June 28, 2026, effective June 25. The updates eliminate prior requirements for stockholders to disclose detailed proposals when requesting record dates for written consent actions. The changes simplify administrative processes for shareholder actions.

Debt Extension Terms

Scilex Holding Company secured an extension for repayment of approximately $29.5 million in outstanding note obligations, including accrued interest. The agreement, signed June 25, 2026, pushes the final due date to September 30, 2026. Oramed received an initial $0.5 million payment upon execution, with an additional $5 million due by July 31, 2026.

Structured Repayment Schedule

Funds received will first cover a $1 million extension obligation before addressing amortization payments tied to a $6.7 million tranche. The remaining balance applies to the larger $29.5 million note. If Scilex fails to meet the September 30 deadline, the first $1.5 million received becomes a non-refundable extension fee, and remaining obligations may convert into Scilex common stock.

Equity Conversion Clause

Under the agreement, Scilex must deliver shares of its common stock if the debt remains unpaid by the deadline. The shares must be registered and free of transfer restrictions, with terms to be mutually agreed upon by both companies. This provision offers Oramed a potential equity stake as collateral.

Financial Implications

The extension provides Oramed with near-term liquidity while deferring larger repayment risks. The $0.5 million upfront payment and $5 million July installment offer immediate relief, though the $1.5 million penalty clause adds pressure on Scilex to comply. Investors will monitor Scilex’s ability to meet the revised timeline.

Regulatory Compliance

Oramed filed the bylaw amendments and debt extension details with the U.S. Securities and Exchange Commission, adhering to the Securities Exchange Act of 1934. The disclosures ensure transparency for shareholders tracking corporate governance and financial restructuring efforts.

Market Reaction Outlook

Analysts may view the bylaw changes as a procedural update, while the debt extension could influence ORMP’s short-term cash flow projections. The equity conversion clause introduces a speculative element, depending on Scilex’s financial stability and stock performance.

 

This article is for informational purposes only and does not constitute financial advice. Please consult a licensed financial adviser before making investment decisions.